2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes
The 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes is an oncology conference featuring leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.
Expert faculty will discuss and analyze the latest scientific findings and practice-changing advances in precision oncology, including the key abstracts relevant to precision oncology presented at the 2023 ASCO Annual Meeting in June 2023.
This conference will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:
- Integrating different platforms available for testing of actionable molecular alterations for identification of targeted therapy options.
- Current and evolving paradigms in precision oncology approach for management of common malignancies.
- Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.
INTERCONTINENTAL HOTEL SAN FRANCISCO
888 Howard Street
San Francisco, CA 94103
To receive the discounted rate, please reserve your room by Friday, September 15, 2023, by visiting the link: Hotel Rooms - 2023 Precision Oncology Summit
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
- Researchers and others involved in the care of cancer patients
Upon successful completion of this educational activity on precision oncology, participants will be able to:
- Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
- Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
- Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
- Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
- Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.
Conference Chair: Dr. Alan Ashworth
Conference Co-Chairs: Dr. Mark Pegram and Dr. Pamela Munster
Associate Chair: Dr. Siddhartha Yadav
DAY 1- October 7th, 2023
All times below are listed in Pacific Standard Time (PST)
7:00 AM– 8:00 AM – REGISTRATION & EXHIBITS
8:00 AM – 8:05 AM – Welcome and introduction – Alan Ashworth, PhD, FRS
8:05 AM – 8:15 AM – Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD
8:15AM – 9AM – Session 1: Precision Oncology
Session Chair: Xiuning Le, MD, PhD
8:15 AM – 8:30 AM – Precision Oncology 101- Christina Lockwood, PhD, DABCC, FAACC, DABMGG
8:30 AM – 8:45 AM – Molecular pathogenesis in cancer – identification of drivers and therapeutic targets- Rachel Schiff, PhD
8:45 AM – 9:00 AM -- Panel Discussion/ Q & A
9:00 AM – 10:00 AM – Session 2: The Revolution in Germline DNA Testing
Session Chair: Marianne Dubard-Gault, MD, MS
9:00 AM – 9:20 AM -- Controversies in germline genetic testing- Pamela Munster, MD
9:20 AM – 9:40 AM – Diagnostic and therapeutic opportunities from germline DNA sequence analysis- Siddhartha Yadav, MBBS, MD
9:40 AM - 10 AM: Panel Discussion/ Q & A
10:00 AM – 10:15 AM – BREAK & EXHIBITS
10:15 AM- 11:15 AM – Session 3: Cell Therapy
Session Chair: Krishna Komanduri, MD
10:15 AM – 10:25 AM – Cell Therapy Overview- Recent Advances and Future Directions- Krishna Komanduri, MD
10:25 AM- 10:35 AM - Novel signaling strategies for CAR-T therapies in Solid Tumors, Greg Allen, MD, PhD
10:35 AM - 10:45 AM- Overcoming immune suppression with novel CAR-T therapies
10:45 AM -10:55 AM- CAR-T therapy for hematologic malignancies: recent advances and future directions- Michael A. Spinner, MD
10:55 AM – 11:15 AM – Cased- Based Panel Discussion with audience Q and A
11:15 AM– 11:55 AM – KEYNOTE- PARP Inhibitors as a New Cancer Therapy Paradigm : History, Challenges and Opportunities - Alan Ashworth, PhD, FRS
11:55 AM – 12:55 PM – LUNCH BREAK & EXHIBITS
Product Theater Sponsored by Merck *Non CME Activity* in Marina Room
Title: A Treatment Option for Certain Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Speaker: David J. Benjamin, MD
12:55 PM – 2:10 PM – Session 4: Precision Medicine in Hematologic Malignancies
Session Chair: Shaji Kumar, MD
12:55 PM – 1:10 PM – Targeting the genetic aberrations in myeloid neoplasms- Karilyn Larkin, MD
1:10 PM – 1:25 PM – Novel therapies in ALL – individualizing therapy- Matthew Joseph Wieduwilt, MD
1:25 PM – 1:40 PM – Individualized therapy in myeloma- Shaji Kumar, MD
1:40 PM- 1:55 PM - Precision medicine in Lymphomas – where are we?- Grzegorz (Greg) S. Nowakowski, M.D., FASCO
1:55 PM – 2:10 PM – Panel Discussion/ Q & A
2:10 PM– 3:10 PM– Session 5: Precision Oncology in Gastrointestinal Malignancies
Session Chair: George A. Fisher Jr. MD
2:10 PM – 2:25 PM – Basic Science in Gastrointestinal Precision Oncology- Hanlee Ji, MD
2:25 PM– 2:40 PM – Translational Science Considerations in Gastrointestinal Malignancies- Chris Chen, MD
2:40 PM– 2:55 PM – Clinical Considerations of Precision Oncology in Gastrointestinal Malignancies- Eric Collisson, MD
2:55 PM- 3:10 PM- Panel Discussion/ Q & A
3:10 PM – 3:25 PM – BREAK & EXHIBITS
3:25 PM– 4:10 PM – Molecular Tumor Board I – Case-based presentations
Session Chair: Howard L. McLeod, PharmD
Case-based presentations: Siddhartha Yadav, MBBS, Chandrikha Chandrasekharan, MBBS, Mark Pegram, MD, Charity Huang, MD
4:10 PM – 5:10 PM – Oral Abstract Presentations
4:10- 4:22 PM: Developing Cell Surface Target Discovery Pipeline in Metastatic Thymic Epithelial Tumors (mTET)- Fatemeh Ardeshir Larijani, MD
4:22- 4:34 PM: Tumor transcriptomic profiling of patients (pts) with Metastatic Castration Sensitive Prostate Cancer (mCSPC) who do not achieve optimal PSA response to intensified androgen deprivation therapy (ADT-I)- Vinay Mathew Thomas, MBBS
4:34- 4:46 PM: Population Health and Cancer Testing (PHACT) Study: A Model for Providing Cancer Gene Panel Testing in a Community-Recruited Multi-Ethnic Population -Leticia Taniwaki, MD
4:46- 4:58 PM: Differences in tumor transcriptomic profile of advanced prostate cancer (PCa) patients (pts) with and without diabetes mellitus (DM)- Gliceida Galarza Fortuna, MD
4:58- 5:10 PM: Immunotherapy in advanced NSCLC by ARID1A mutational status: A case-control analysis by ctDNA - Ebaa Al- Obeidi, MD
5:10 PM – Poster viewing and reception
DAY 2- October 8th, 2023
7:00 AM– 8:00AM – REGISTRATION & EXHIBITS
8:00 AM– 9:00 AM – Session 6: Precision Medicine Clinical Science Symposium: Breast Cancer
Session Chair: Mark Pegram, MD
8:00 AM– 8:15 AM – Update of Basic Science Developments in Precision Oncology for Breast Cancer- Joshua Gruber, MD. PhD
8:15 AM – 8:30 AM – Translational considerations in Precision Oncology in Breast Cancer- Christina Curtis, PhD, MSc
8:30 AM- 8:45AM – Clinical Developments in Precision Oncology for Breast Cancer- Hope Rugo, MD, FASCO
8:45 AM– 9:00 AM– Panel Discussion/ Q & A
9:00 AM – 10:00 AM – Session 7: Precision Medicine Clinical Science Symposium: Lung Cancer
Session Chair: Jonathan Wesley Riess, MD, MS
9:00 AM– 9:15 AM – Basic Science/Molecular Pathogenesis of Lung Cancer- Alex A. Adjei, MD, PhD, FACP
9:15 AM – 9:30 AM – Translational Science Update of Precision Oncology Methods in Lung Cancer- Joel W Neal, MD. PhD
9:30 AM – 9:45 AM – Clinical Application of Precision Oncology in Lung Cancer- Millie Das, MD
9:45 AM- 10:00 AM- Panel Discussion/ Q & A
10:00 AM– 10:15 AM – BREAK & EXHIBITS
10:15 AM – 11:15 AM – Session 8: Precision Medicine in Genitourinary Oncology
Session Chair: Alice Fan, MD
10:15 AM– 10:30 AM – Basic Science of Precision Oncology in Genitourinary Oncology- Russell K Pachynski, MD
10:30 AM – 10:45 AM – Translational Science in Genitourinary Precision Oncology- Arlene O Siefker-Radtke, MD
10:45 AM – 11:00 AM – Clinical Considerations of Precision Oncology in Genitourinary Malignancies- Ulka Vaishampayan, MD
11:00 AM- 11:15 AM- Panel Discussion/ Q & A
11:15 AM– 12:15 PM – Session 9: Precision Oncology in Solid Tumor Malignancies
Session Chair: Michael Wagner, MD
11:15 AM– 11:30 AM – Tissue-Agnostic Drug Development in Precision Oncology- Peter J. O'Dwyer, MD
11:30 PM– 11:45 AM – Precision Medicine in Sarcoma Management- Sant Chawla, MD
11:45 PM– 12:00 PM – Precision Medicine in Dermatologic Malignancies- Pauline Funchain, MD
12:00 PM - 12:15 PM- Panel Discussion/ Q & A
12:15 PM– 1:15 PM – LUNCH & EXHIBITS
1:15 PM – 2:15 PM – Molecular Tumor Board II -- Case-based presentations
Session Chair: Jason Brown, MD, PhD
Case-based Presentations: Michelle Melisko, MD, Marianne Dubard-Gault, MD, MS, Jason Brown, MD, PhD
2:15 PM – 3:15 PM – Session 10: Implementation of Precision Oncology into the Diagnostic and Therapeutic Armamentarium
Session Chair: Raid Aljumaily, MD
2:15 PM– 2:30 PM -- Disparities in Precision Oncology -- Improving Access to Evidence-based Testing for Targeted Therapies
2:30 PM – 2:45 PM – Molecular Imaging in Precision Oncology- Andrei Iagaru, MD
2:45 PM– 3:00 PM -- Machine-Learning (ML) in Precision Oncology – Predicting Target Structure- Manish Kohli, MD
3:00 PM- 3:15 PM- Panel Discussion/ Q & A
3:15 PM Chairperson’s Concluding Remarks
A limited number of rooms have been reserved at the InterContinental Hotel San Francisco for attendees and exhibitors of the 2023 Precision Oncology Summit at a discounted rate of $329/night. Hotel check-in time is 4:00 pm on the day of arrival and check-out time is 11:00 am on the day of departure. For a smooth and successful stay, please advise the hotel staff of your estimated time of arrival and departure, daily itineraries, and any other pertinent information.
Please reserve your room by the cut-off date, Friday, September 15, 2023, by visiting the link below:
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
- 12.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 12.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 12.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.50 Contact Hours.
Physicians (non-industry) - $350
Non-physician HCP (non-industry) - $250
Industry representatives - $1250
Fellow or resident - $200
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
- No refunds will be issued if registration is cancelled after that date.
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.